Medications with Proven Links to Cleft Palate
Methotrexate has the strongest evidence for causing cleft palate, with a 2.6-fold increased risk of oral clefts when used during pregnancy, and must be discontinued at least 3-6 months before conception 1, 2, 1.
Medications with Established Teratogenic Risk for Cleft Palate
High-Risk Medications (Absolute Contraindications)
Methotrexate is the most clearly documented medication linked to cleft palate:
- 2.6-fold increased risk of oral clefts compared to no exposure 1
- Also causes 3.4-fold increased risk of cardiovascular defects 1
- Must be stopped at least 3 months before conception (some guidelines recommend 6 months) 2, 1
- If pregnancy occurs while taking methotrexate: immediately discontinue and refer for obstetric counseling 1
- Folic acid supplementation should be initiated or continued to reduce methotrexate-related adverse effects 1
Antiepileptic Drugs (AEDs)
Valproic acid carries significant risk:
- 11.9-fold increased risk for spina bifida 3
- 5.8-fold increased risk for cleft palate 3
- Approximately 35 infants per year in the US could be born without cleft palate if valproic acid were avoided during pregnancy 3
Carbamazepine has moderate risk:
- 2.4-fold increased risk for cleft palate 3
- Confirmed cleft-inducing effect in multiple studies 4
- Approximately 5 infants per year in the US could be born without cleft palate if carbamazepine were avoided 3
Phenytoin is also associated with cleft palate:
- Confirmed orofacial cleft-inducing effect 5, 4
- 2.6%-6.4% risk of major congenital malformations 5
- Specific teratogenic risk for cardiac defects, cleft palate, and club foot 5
Phenobarbital:
Corticosteroids
Systemic corticosteroids (prednisolone, prednisone) have conflicting but concerning data:
- Some studies show 3-fold increased risk for isolated cleft lip ± cleft palate when used in first trimester 6, 7
- However, newer studies and registries suggest glucocorticoids may not pose teratogenic risk for orofacial clefts 2
- The evidence remains mixed, but caution is warranted in first trimester use 6, 7
- When severe asthma or autoimmune disease requires treatment, the maternal benefit may outweigh fetal risk 6
Antihistamines (Uncertain/Low Risk)
Diphenhydramine has some concern:
- One case-control study suggested association with cleft palate 8
- However, recent larger studies have not detected increased risk 8
- The concern has "yet to be sufficiently refuted" 8
- Most antihistamines show excellent safety records overall 8
Hydroxyzine:
- Should be used cautiously in first trimester based on animal data 8
Ondansetron (Minimal Risk)
Ondansetron has very small absolute risk:
- Absolute risk of orofacial clefting increases from 11 cases per 10,000 births to 14 cases per 10,000 births 9
- This represents only 3 additional cases per 10,000 births 9
- Most robust studies (>88,000 first trimester exposures) show no overall increased malformation rate 9
- The small increased risk should be balanced against risks of poorly managed hyperemesis gravidarum 9
Clinical Algorithm for Medication Management
Preconception Planning:
- Stop methotrexate 3-6 months before attempting conception 2, 1
- Switch from valproic acid to safer alternatives (levetiracetam or lamotrigine preferred) 5
- Minimize or switch from carbamazepine/phenytoin if possible 5, 3
- Use monotherapy at lowest effective dose for seizure disorders 10
First Trimester Exposure:
- Methotrexate: Immediate discontinuation, folic acid supplementation, obstetric counseling (termination not mandatory) 1
- Valproic acid/carbamazepine: Switch to safer AED if seizure control allows 5
- Systemic corticosteroids: Weigh maternal disease severity against small cleft risk 6, 7
Common Pitfalls to Avoid:
- Do not assume all antihistamines carry equal risk—most are safe 8
- Do not avoid ondansetron unnecessarily in severe hyperemesis—the absolute risk increase is minimal 9
- Do not stop corticosteroids abruptly in severe asthma or autoimmune disease—uncontrolled maternal disease poses greater fetal risk 6
- Do not use polytherapy for seizures when monotherapy is possible 10